TypeOnline Course
Student Enrolled7
(1 ratings)
Price$1200 / Rs. 46000$840 USD / 36800 INR.
Buy NowBook Now
Loading

Admission Process

Sign in or create account at www.nckpharma.com with all details and make the course fees payment to start the course

Sign Up Now

KPE - C- 024 KPE's Executive Program in Pharmaceutical Global Business

introduction

Course Description

Course Objective

Course duration

Features

Eligibility

Admission

Course Deliverable

Add on Certification

Related Courses

pharma global business course

Executive Program in Pharmaceutical Global Business provides hands on training to enhance skill competency of middle and top level managers. This course suits for the working professionals of pharmaceutical and biopharmaceutical industry. In this self paced learning, one can experience the real life work simulations for pharma and biopharmaceutical industry. Skills which are most necessary for successful in the biopharmaceutical and pharmaceutical competitive landscape is covered in depth. 

  • Code: KPE-C-024
  • Course Title: KPE’s Advance Diploma in Pharmaceutical Global Business
  • Type of the course: Self paced Online Course

Course Description

Executive Program in Pharma Global Business is little different from other other management business courses. Other Business Management courses concentrate narrowly on a diverse function or piece of the business—accounting, finance, marketing, production, human resources, or information systems, strategic management. But here it is strategic management
This course focus on the real life working on the whole spectrum of pharmaceutical and bio-pharmaceutical strategic business and management. The center of attention is the total pharma and biopharma enterprise–-the industry and competitive environment in which it operates, its long-term direction and strategy, its resources and competitive capabilities, and its prospects for success.

Key factor

pharma global business online courseThroughout the course, the spotlight will be trained on the foremost issue in running a pharmaceutical and biopharmaceutical business enterprise: “What must managers do, and do well, to make the pharmaceutical company a winner in the game of business?

Strategic Orientation

The answer that emerges, and which becomes the theme of the course, is that good strategy-making and good strategy-execution are the key ingredients of company success and the most reliable signs of good management. The mission of the course is to explore why good strategic management leads to good business performance, to present the basic concepts and tools of strategic analysis, and to drill you in the methods of crafting a well-conceived strategy and executing it competently.

You’ll be called on to probe, question, and evaluate all aspects of a company’s external and internal strategic situation. You’ll grapple with sizing up a company’s standing in the marketplace and its ability to go head-to-head with rivals, learn to tell the difference between winning strategies and mediocre strategies, and become more skilled in spotting ways to improve a company’s strategy or its execution. In the midst of all this, another purpose is accomplished: to help you synthesize what you have learned in prior business courses.

KPE’s Executive Program in Pharmaceutical Global Business course in which you’ll see how the various pieces of the business puzzle fit together and why the different parts of a business need to be managed in strategic harmony for the organization to operate in winning fashion.

Objective of the course

  • The course helps participant to think strategically about a pharmaceutical and Biologic company, its present business position, its long-term direction, its resources and competitive capabilities, the caliber of its strategy, and its opportunities for gaining sustainable competitive advantage.
  • To develop clear cut understanding on drug discovery to development to commercialization process effectively, to strategise the pharmaceutical business in regulated, semi-regulated and unregulated market. Pharmaceutical Global Business Course
  • Executive Program in Pharmaceutical Global Business provides the skill training regarding branding activities and strategic analysis in a variety of competitive situations and, especially, to provide you with a stronger understanding of the competitive challenges of a global pharmaceutical business environment.
  • To give you hands-on experience in crafting pharmaceutical branding, business strategy, reasoning carefully about strategic options, using what-if analysis to evaluate action alternatives, and making sound strategic decisions.
  • This Global Pharma Business course helps one to acquaint with the managerial tasks associated with implementing and executing company growth strategies, drill in the range of actions managers can take to promote competent strategy execution, and give you some confidence in being able to function effectively as part of a company’s strategy-implementing team.
  • The course helps to develop the decision making skills for managers. Therefore, it helps one to learn how to assess business risk, and improve your ability to make sound decisions and achieve effective outcomes.

Course Duration

1 Year from the date of admission.

Features of the course

  • Self paced learning – 24×7 online access – learn at your convenience.
  • Orientation to job related practical aspects of different domain of the pharmaceutical and biopharmaceutical operations.
  • Simulation to real life working to enhance the practical skills.
  • Access to Industry Databank, case studies, simulations.
  • Attend Lectures of all different chapters / study content.

Minimum qualification for participation of this course is Graduation in any discipline with more than 24 months of work experience in middle and top management. Work Experience is mentioned is mandatory for admission into this course. Work Experience certificate / proof need to be provided at the time of admission.

FAQ RELATED TO THE COURSE

Frequently asked questions

Read FAQs

ADMISSION PROCESS

  • Course contains 34 study modules in the form of eBooks. Therefore, you can save the eBooks in your system.
  • You can download the study modules by login to your dashboard.
  • Immediately upon admission, course participant can instantly accessing the course.
  • Executive Program in Global Pharmaceutical Business is online 24×7 learning. Hence, course participants can access the lectures at their own convenience.
  • While attending lectures, course participant can also download the lecture handout and save for reference.

  • The participants of Global Business Registrant will get two add on certification.
  • Participant can choose add on courses of any 1 month or 1 week certification course.
  • Participant can activate the add on course anytime during 1 year active course duration.
  • On completion of add on course, participant will be issuing course certificate.
  • You can activate this add on course anytime during the active 1 year course tenure.

Course Syllabus & Orientation:

Section 1Global Pharmaceutical R&D: Discovery to Development
Lecture 1Drug Regulation Fundamentals
Lecture 2Investigational New Drug Application (INDA)
Lecture 3New Drug Application (NDA)
Lecture 4Basic concept and understanding of the Generic Drug
Lecture 5Abbreviated New Drug Application (ANDA) Filing
Lecture 6Review on Drug Discovery and Development
Lecture 7Generic Drug User Fees Act (GDUFA)
Lecture 8Prescription Drug User Fees Act (PDUFA)
Lecture 9Handling of orange book
Lecture 10USFDA expedited programs
Lecture 11Practical Training on INDA, NDA, ANDA filing
Lecture 12505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA
Lecture 13Authorized Generics: Key Understanding
Lecture 14Exploratory IND Vs. Traditional IND
Lecture 15Patents Vs. exclusivity
Lecture 16Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE) | NCE & NCI Exclusivity | GAIN Exclusivity | Pediatric Exclusivity | 180 days exclusivity
Lecture 17Orphan Drug & Orphan Drug Act
Lecture 18Clinical Research : Detailed Understanding
Lecture 19Clinical Trial Protocol Writing
Lecture 20Ethics in Clinical Research
Lecture 21FDA Forms and How to fill the resources
Lecture 22Strategic Discussion: PreIND, EOP1, EOP2 - What to expect !
Lecture 23Advance Learning on 505B2 Pathway
Lecture 24Importance and Significance of Phase 2b Clinical Trial 
Lecture 25Informed Consent | Practical Training on Preparing ICF | Templates
Section 2Innovation Management in Pharmaceutical & Biopharmaceutical Industry
Lecture 26USPTO - Introduction
Lecture 27Patent
Lecture 28Patent - Practical on search and filing - USPTO
Lecture 29Trademark - Practical on TM Search & Registration Process - USPTO
Lecture 30Trademark - Practical on TM Search USPTO
Lecture 31Trademark Search assignment USPTO
Lecture 32Patent - Practical on search and filing in Indian Patent Office
Lecture 33Trademark - Practical on TM Search & Registration Process in India
Lecture 34Fundamental Understanding of Patent, Trademark Licensing and related terminology
Lecture 35Patent Cliff
Section 3Global Strategic Management
Lecture 36Understanding of Regulatory Strategies
Lecture 37Advance study on Para IV Filing
Lecture 38Para IV Notices
Lecture 39Evergreening - Patent Life Extension Strategies
Lecture 40Pay For Delay Strategy
Lecture 41REMS Strategic Planning 
Lecture 42Compulsory Licensing
Lecture 43Licensing & Technology Transfer
Lecture 44In-Licensing Vs. Outlicensing
Lecture 45LOE Strategies for Innovator Brands with case study
Lecture 46Paediatric Exclusivity and Paediatric Study Plan Development
Lecture 47Drug Repurposing
Lecture 48Licensing - Advance Learning 
Lecture 49Detailed Understanding on 505(b)(2) VS. Suitability Petition : Case Based Learning
Lecture 50NCE Vs. 505b2 application - Case Based Learning 
Lecture 51FTF - 180 Days Exclusivity - Case Based Learning
Lecture 52Classic case study of the 505b2 filing : Case Based Learning
Lecture 53Strategic Planning in Combating 30 months stay strategies of innovator company- Case Based Learning
Lecture 54Pipeline in a Molecule
Lecture 55Emergency Use Authorization (EUA)
Section 4Basic Fundamental of Pharma Production & Plant Management
Lecture 56Definition of GMP
Lecture 57Premises & Plant Layout Designing
Lecture 58Sanitation and Hygiene
Lecture 59Equipment Modules
Lecture 60Production Modules
Lecture 61Documentation
Lecture 62Quality Control
Lecture 63G7 Lecture Product Complaint
Lecture 64G8 Lecture Storage Module
Lecture 65ISO and ISO Audits
Lecture 66CAPA
Section 5Global Business : European Union - Regulatory & Strategic Planning
Lecture 67Introduction to EU Regulation 
Lecture 68Orientation to European Countries and National Regulatory Bodies
Lecture 69Orientation to European Countries and National Regulatory Bodies
Lecture 70Overview of EU Regulation
Lecture 71EMA and EMA Authorisation Process
Lecture 72Summary of Product Characteristics
Lecture 73Compassionate Use
Lecture 74EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 75Validity of the EU MA  - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 76Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 77EU Orphan Medicinal Products Regulation
Lecture 78Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 79Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 80Summary of Product Characteristics 
Lecture 81Compassionate Use
Lecture 82MHRA - UK Regulation 
Lecture 83The 'sunset clause' for marketing authorisation of pharmaceuticals
Lecture 84EU variation - Types, Requirement & Planning - IA, IAIN, IB, II ; US FDA Variation AR, CBE-0, CBE-30, PAS - Strategic Discussion | Similarities & Differentiation
Lecture 85EU Prime Designation 
Lecture 86Accelerated assessment by EMEA
Lecture 87EU Adaptive Pathway
Lecture 88European public assessment report (EPAR) - Importance, Component, Management, Updation 
Lecture 89SPOR  - Concept of Master Data Management  
Section 6Biopharmaceutical - Regulatory and Strategic Management
Lecture 90Introduction : Biopharmaceuticals
Lecture 91Classification of Biopharmaceutical 
Lecture 92Introduction to Biosimilar 
Lecture 93Chemical Drugs Vs. Biologic Drugs
Lecture 94Principle of Naming of Biologics
Lecture 95Current Trends in Biopharmaceutical Market
Lecture 96Global Biologics Market – By Product
Lecture 97Market Share of Different Class of Biopharmaceuticals
Lecture 98Blockbuster Biologic - Classifications,  Indications, Global Sales
Lecture 99Market Understanding: Leading Biosimilar Companies
Lecture 100Market Understanding: Top Leading Brands
Lecture 101Recombinant protein
Lecture 102Monoclonal Antibodies Vs. Polyclonal Antibodies
Lecture 103Monoclonal Antibodies
Lecture 104Synthetic Immunomodulators
Lecture 105Production of Monoclonal Antibodies
Lecture 106Cytokines
Lecture 107Interferon
Lecture 108Erythropoiesis-stimulating agent
Lecture 109Biological Licensing Application (BLA)  | 351(a) application | Form 356h | Differentiation with NDA | Timeline | Handling FDA queries
Lecture 110Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 111Purple Book: Significance | Searching | Assignments
Lecture 112Biosimilar Development Process
Lecture 113Strategic Consideration for Biosimilar Development 
Lecture 114Bio-Manufacturing Process Information
Lecture 115Studies required for approval of biosimilar
Section 7Drug Registration Dossier
Lecture 116MA Submission Dossier Management
Lecture 117CMC Dossier & Compliance Management
Lecture 118Introduction to Electronic Common Technical Document (ECTD)
Lecture 119Advance Practical Training on Dossier Preparation focusing on drug registration in export countries
Lecture 120Modules on Stability Study 1
Lecture 121Importance of effective dossier management
Lecture 122Certificate of Analysis
Lecture 123Detailed Understanding on ANDA Submission Dossier 
Lecture 124Prior Approval Submission 
Lecture 125Detailed Understanding on ANDA Fees
Lecture 126Discussion on 85 common deficiency in CTD submission dossier
Lecture 127Key Consideration for Drug Master File Preparation and Submission 
Lecture 128Practical Understanding on Drug Master File Preparation and Submission
Lecture 129Associated Learning: Site Master File - Detailed Understanding 
Lecture 130DMF Completeness Assessment
Lecture 131Drug Master File - Fees
Lecture 132Drug Master File - Global Perspective [Across Different Regions]
Lecture 133Site Master File
Section 8Plant Inspection and Audit Handling
Lecture 134Data Integrity issues in Pharmaceutical Industry
Lecture 135Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter 
Lecture 136CAPA
Section 9Introduction to Pharma Brand Manager
Lecture 137Pharma Product Management
Lecture 138Detailed Understanding of Product Management Job
Lecture 139Classification of Doctors
Section 10Marketing Orientation for Business Manager
Lecture 140Marketing Orientation for Product Manager
Lecture 141Why Is Market Research Important in Pharmaceutical Business?
Lecture 142Product Life cycle 
Lecture 143Advance - Strategic Planning in Product Life cycle Management
Lecture 144Segmentation
Lecture 145Pricing
Lecture 146Distribution Channel in Pharmaceutical Industry 
Lecture 147A Pharmaceutical Segmentation outlook
Lecture 148Promotion in Pharmaceutical Industry : Communication Model, Effective promotional communication, Push Vs. Pull Strategy and Buying Decision Process
Lecture 149Practical understanding on Prescription Accelerating Materials used in pharmaceutical promotion
Lecture 150Setting and Quantifying Promotional Objectives
Lecture 151Break even analysis
Lecture 152Method of Promotional Budgeting
Lecture 153Basics of Advertising
Lecture 154The Advertising agency
Lecture 155Brand Recall | Brand Recognition |Top of mind - How to calculate brand recall value?
Lecture 156Advertising Planning - ATL, BTL, TTL activities
Lecture 157Target Audiences for Pharma Promotion : Types and Specialization
Lecture 158Business segments of Pharmaceutical Companies
Lecture 159Target Audience Selection Based on Products
Section 11Practical Training on Pharma Brand Logo Development
Lecture 160Brand Logo - Introduction
Lecture 161Purpose of Brand Logo
Lecture 162Component of Brand Logo
Lecture 163Trademark Registration
Lecture 164Trademark - Practical on TM Search
Lecture 165Trademark Search assignment
Lecture 166How to design excellent brand logo?
Lecture 167How to design excellent brand logo?
Lecture 168Color Systems - RGB & CMYK
Lecture 169Few Case Studies related to brand names and logos
Lecture 170Brand Logo - Simulation
Lecture 171Colour Trademarking in Pharma Branding
Lecture 172How to protect pharma brands globally?
Lecture 173Rebranding in Pharmaceuticals
Lecture 174Brand Logo Development: Real Life Simulation
Lecture 175Brand Tagline - Punchline
Lecture 176Pharma Brand Name Generator
Section 12Advance Pharma Brand Management - 1
Lecture 177Fundamental of Pharma Marketing Plan 
Lecture 178Basic Understanding how to launch a pharmaceutical product into the market 
Lecture 179Practical Training on Marketing Plan Preparation with real life example
Lecture 180Marketing Campaign Development : Importance of Target Audience Segmentation for effective targeting 
Lecture 181New Product Launch Framework
Lecture 182Sectional Development of Marketing Plan
Lecture 183Decide about brand USP -What to promote 
Lecture 184Sample Marketing Plan
Lecture 185How to prepare promotogram. Download sample Promotogram
Lecture 186Importance and Handling of Cycle Meeting and its importance 
Lecture 187Brand Launch Case Study
Lecture 188Aristada - Launch Case Study
Lecture 189CSR Campaign
Lecture 190Cost Based Working for Sample Allocation
Lecture 191Increase the brand reach with advance segmentation
Lecture 192Concept of uniform branding for better brand acceptability
Lecture 193Concept of Brand Differentiation
Lecture 194Brand Plan to Marketing Campaign - Objective setting to effective execution
Section 13Digital Pharma Marketing
Lecture 195Pharma Packaging Case Studies
Lecture 196Inbound and outbound marketing in pharma | Types of inbound and outbound marketing 
Lecture 197Digital Media Marketing Macro-Environment Analysis | Mapping of online market place | Internet marketing conversion process | Conversion Process Digital VS. Traditional | Publisher revenue model | Affiliate revenue model
Lecture 198Digital Media Marketing Micro - Environment Analysis | Web server | Web browser | http vs. https - Significance and hands on understanding | Privacy and ethical issues in internet marketing
Lecture 199Digital marketing strategy development | Planning process | E-Marketing Plan | Planning for MNC Vs. Start Up | Strategic Outcome measurement
Lecture 200Relationship marketing using digital platform | CRM | Concept of permission marketing | User Satisfaction and loyalty management | Feedback mechanism
Lecture 201Campaign planning for digital media | Goal setting | Tracking | Campaign insight | Segmentation and targeting | Message Development | Media Mix Selection | Media scheduling | Practical understanding to campaign performance matrics | CPC | CPA | PPC | ROI | CPS
Lecture 202Search Engine Optimization | Search Engine Marketing | Social Media Marketing
Lecture 203Web Analytics - Tool and Implementation 
Lecture 204Web Host - Check the hosting details 
Lecture 205Page Speed- importance and practical understanding | Check the web speed 
Lecture 206Keyword | Keyword Planning for SEO and SEM | Keyword Planner
Lecture 207Mobile Responsive | Tracking the Site 
Lecture 208HCP sites and Patient Site
Lecture 209Google Ad - Practical Training on Campaign Development and Execution
Lecture 210Digital Marketing Strategies for innovator brand | Pre launch - comuing soon, DSE Marketing | Launch activities - Day of approval (DOA) site | FDA Compliance | FDA 2253 Filing
Lecture 211Brand Portal Development
Lecture 212Relationship Marketing : KOL Management and Patient Advocacy Group 
Lecture 213Public Relation - PR firm | PR Campaign | Press Release | Technical understanding of press release writing | Digital Press Release
Lecture 214Developing Ad - Pharmaceutical Prescription, OTC Vs FMCG Brands
Lecture 215Difference between FMCG and OTC Brand Ad
Lecture 216Digital Marketing Techniques
Lecture 217Video Marketing
Lecture 218Video Marketing Techniques For Small Business Owners
Lecture 219Promoting Brand through Article Advertising and Marketing
Section 14Analytics
Lecture 220Moving Average | Moving Annual Total | YTD | How to calculate 
Lecture 221Compound Annual Growth Rate | CAGR Calculation
Lecture 222Analytical Approach in Determining Brand Potential with case study
Section 15Fundamental understanding in Finance
Section 16Project & Portfolio Management
Lecture 224Introduction: Project Management
Lecture 225Difference between Project and Program
Lecture 226Role and Responsibility of Project Leader
Lecture 227Project Constraint & Effective management of Project Constraint | Role of Project Manager
Lecture 228Key to Project Success
Lecture 229Review Test
Lecture 230PERT, CPM, Critical Path, Project Diagram and its components
Lecture 231Project Tracking in Drug Discovery Projects
Lecture 232Project Benchmarking through a Consortium
Lecture 233Cycle Times (Stage or phase lengths)
Lecture 234The proof of concept (POC) milestone in pharma Drug Development Projects
Lecture 235What is a milestone chart?
Lecture 236Project Termination and Project Reinitiation
Lecture 237Asset Tracking
Lecture 238Levels of Project and Portfolio Management
Lecture 239Functions of Portfolio Management Team
Lecture 240Importance of Periodic Portfolio Reviews
Lecture 241Portfolio Prioritization
Section 17Business Development Skill Training
Lecture 242Pharma BusiBusiness Development Job Functionality | Strategic Planning Process | Knowledge Area of Business Development | Lead targeting | Licensing term sheets
Lecture 243Portfolio Management Process | Portfolio Characteristics | Portfolio Analysis | Balancing the Portfolio | BD and Strategic Planning Department 
Lecture 244Identifying the corporate Need of business development | Objective – Strategy - Tactics | Portfolio constraints | SWOT | Numerical SWOT
Lecture 245Profiling and Searching | Objectives | Search Database | Creating Opportunity Anatomy for deal analysis | Mind Mapping | Searching Tools and Techniques - Web Search | Conference | Confidentaility - CDA | MTA
Lecture 246Numerical SWOT Practical training
Lecture 247Modelling and Deal Valuation - Top Down Model | Epidemiology data method | Complex Model | Forecasting | Heuristic or ‘prophesy’ method | Different value perspectives | Deal Structuring Structuring the deal
Lecture 248Market Size Determination - Market Share | Relative Market Share | Total Vs. Actual Vs. Penetrated Market
Lecture 249Forecasting : Tools and Techniques
Lecture 250Market Sizing & Forecasting Case Study
Lecture 251Royalty Management - Royalty structuring | Royalty Calculation Method| Tiered Royalties | Terms | Royalty Reductions | Royalty Stacking - Concept and Calculation | Minimum Annual Royalties | Reach through royalties
Lecture 252Average Royalty Rates
Lecture 253Factor affecting the Royalty Rate in Pharmaceutical and Biopharmaceutical Deal
Lecture 254Distribution Licensing | Geography | Indication Splitting | Execlusive and Non-Exclusive Licensing | Sub Licenses
Lecture 255Acquisition in Pharma  | Product Acquisition| Company Acquisitions| Steps in acquisition | Financing acquisition deals | Trademark Assignment Process
Lecture 256Join Ventures in Pharmaceutical and Biopharmaceutical Industry
Lecture 257SPECIAL PURPOSE VEHICLES (SPV)
Lecture 258Indication Splitting | Concept | Implementation feasibility analysis 
Lecture 259Types of Deals from Discovery to Commerialication
Lecture 260Review: What are the fundamental areas of business development
Lecture 261Licensing Term Sheet | Content Structuring | Sample Term Sheet
Lecture 262Licensing Payment Scheduling: Different Types
Lecture 263Valuation Methods: DCF | rNPV | Sunk Cost Method | Comparables | Sum of Parts | Deterministic Vs. Probabilistic rNPV |  Peak Sales - Max-Min Approach
Lecture 264Valuation Methods: EBITDA method of valuation | Enterprise Value and Enterprise Multiple Calculation
Lecture 265Negotiation Skill Training for Business Development and Strategic Management Professionals
Lecture 266Business Development Simulation and Decision Making | Early Stage VS. Late Stage Valuation Methodology | Stair Step Model
Lecture 267Licensing Agreement : Confidentiality Agreement | MTA | A deed of Assignment | Exclusive | Non-Exclusive License | Sole License | Components - Terms - Duration - Key Considerations
Lecture 268Step By Step Implementation of Licensing Deal by Business Development Team 
Lecture 269Due Diligence Activities in Pharmaceutical Licensing
Lecture 270Pharma Business Development - Competency Test. Check your competency
Lecture 271Co-promotion & Co-marketing strategy in pharma industry 
Lecture 272Concept of Reverse co-promotion in pharma industry
Lecture 273Importance of Publications in Pharmaceutical Industry 
Lecture 274Juxtapid Case Study 
Lecture 275New Indication Approval Process and Promotion
Section 18GCC - Pharma Business
Lecture 276GCC Pharma Market
Lecture 277Export to GCC Market
Lecture 278Drug Registration in Saudi Arabia
Lecture 279Drug Registration in UAE
Lecture 280Drug Registration in Kuwait
Lecture 281Drug Registration in Bahrain
Lecture 282Drug Registration in Oman
Lecture 283Documentation Required for the GCC countries 
Lecture 284Comparison of the GCC Registration Requirement with other Regulatory Agencies
Section 19Pharma Business Africa
Lecture 285African Continent Overview
Lecture 286African Pharma Market
Lecture 287Drug Registration - African medicines regulatory
Lecture 288Basic Export Requirement for African Countries
Lecture 289Export Documentations & Important Concepts
Lecture 290Nigeria  - Drug Registration
Lecture 291Drug Registration in Algeria
Lecture 292Drug Registration in Ethiopia
Lecture 293Drug Registration in Kenya
Lecture 294Drug Registration in Egypt
Lecture 295Drug Registration in Ghana
Lecture 296Drug Registration in Botswana
Lecture 297Drug Registration in Uganda
Lecture 298Drug Registration in Sudan
Lecture 299Drug Registration in Morocco
Lecture 300Drug Registration and Regulation in Zimbabwe
Lecture 301Drug Registration and Regulation in Senegal
Lecture 302Drug Registration in Tanzania
Lecture 303Drug Registration in Namibia
Lecture 304Drug Registration in South Africa
Lecture 305Drug Registration in Zambia
Lecture 306Drug Registration in South Africa
Section 20Latam Pharma Market
Lecture 307Introduction to Latam 
Lecture 308Drug Registration and Regulation in Argentina 
Lecture 309Drug Registration and Regulation in Bolivia
Lecture 310Drug Registration and Regulation in Brazil 
Lecture 311Drug Registration and Regulation in CHILE
Lecture 312Drug Registration and Regulation in Colombia
Lecture 313Drug Registration and Regulation in Mexico
Section 21ASEAN
Lecture 314ASEAN Drug Regulatory Affairs
Lecture 315Asean Geography 
Lecture 316Drug Registration in Brunei 
Lecture 317Drug Registration in Malaysia 
Lecture 318Drug Registration in Cambodia 
Lecture 319Drug Registration in Mayanmar 
Lecture 320Drug Registration in Philippines 
Lecture 321Drug Registration in Singapore 
Section 22Other Country and Business Regioans
Lecture 322Japan
Lecture 323India
Lecture 324China | ***Updated July 2020 DRR & DMR regulation
Lecture 325Australlia
Lecture 326Russsia